Neusoft Medical Systems launches China's first photon-counting CT with NMPA approval

August 28, 2025 | Thursday | News

This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector

Neusoft Medical Systems has announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector.

Photon-counting CT (PCCT)  is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector to capture and convert each X‑ray photon directly into a digital signal. This direct approach delivers images with far greater clarity, reduces radiation exposure for patients, and improves the ability to distinguish between different types of tissue.

For patients, these advances mean clearer visualization of tiny blood vessels in the heart, earlier detection of small tumors, more accurate identification of neurological conditions, and safer lung examinations with reduced exposure to radiation. The system's ultra-high resolution also helps doctors detect diseases at earlier stages, when treatment can be more effective and outcomes significantly improved.

To maximise clinical and research value, the NeuViz P10 integrates four innovation platforms: NeuPhoton Counting, Photon Supersonic, Photon Intelligence, and Photon Research. Together, these platforms deliver faster scans, safer imaging, intelligent workflow support, and expanded opportunities for clinical research.

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls